Impaired IL-4 phosphorylation of STAT6 in EBV transformed B-cells.
BACKGROUND
The Interleukin-4 signal transducer and activator of transcription 6 (IL-4-STAT6) signaling pathway plays a pivotal role in regulation of gene transcription. We have previously identified a defective STAT6 activational phenotype in response to IL-4 in patients from our familial Inflammatory Bowel Disease registry. This has been termed Stat6(null) and Stat6(high) is the normal phenotype. The purpose of this study was to investigate the defect in Stat6 activation in Stat6(null) cells.


METHODS
Stat6(null) and Stat6(high) Epstein Barr virus transformed cell lines were stimulated with 10 ng/mL of IL-4 for 0, 10, 30, or 60 min and cytoplasmic and nuclear proteins harvested. Western blot for STAT6, phosphorylated STAT6 (pSTAT6), Janus Kinase (Jak)1 and Jak3 was performed. Cells were also cultured for 48 h and interferon gamma (IFNgamma) measured in the supernatant. Additional cells were cultured with 20 ng/mL of IFNgamma for 90 min or 5 ug of antibody to IFNgamma for 48 h, and then stimulated with IL-4.


RESULTS
There were no differences in cytoplasmic STAT6 in Stat6(null)versus Stat6(high) cells. In Stat6(high) cells, STAT6 was rapidly phosphorylated and translocated to the nucleus. In Stat6(null) cells there was minimal phosphorylation and translocation of pSTAT6 to the nucleus. Spontaneous secretion of IFNgamma by Stat6(null) cells was significantly higher than Stat6(null) cells. Addition of IFNgamma decreased pSTAT6 in Stat6(high) cells to Stat6(null) levels while blocking IFNgamma increased baseline pSTAT6 in Stat6(null) cells to levels similar to Stat6(high) cells.


CONCLUSIONS
This suggests that the spontaneously produced IFNgamma in the Stat6(null) cell lines suppresses STAT6 function and creates the Stat6(null) phenotype.
Poritz
Lisa S
LS
Department of Surgery, The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania 17033, USA. lporitz@psu.edu
Zhang
Wen Jie
WJ
Thompson
Jennifer
J
Boyer
Morgan
M
Clark
Clarence
C
Koltun
Walter A
WA
D001402:B-Lymphocytes / Q000187:drug effects / Q000502:physiology* / Q000821:virology; D015153:Blotting, Western; D002460:Cell Line; D002461:Cell Line, Transformed; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D015847:Interleukin-4 / Q000378:metabolism* / Q000494:pharmacology; D053613:Janus Kinase 1 / Q000378:metabolism; D053616:Janus Kinase 3 / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects / Q000502:physiology*; D010766:Phosphorylation; D019948:Receptors, Interleukin-4 / Q000502:physiology*; D012042:Registries; D050800:STAT6 Transcription Factor / Q000172:deficiency / Q000378:metabolism*
D019948:Receptors, Interleukin-4; D050800:STAT6 Transcription Factor; C494101:STAT6 protein, human; D015847:Interleukin-4; D007371:Interferon-gamma; C507904:JAK1 protein, human; D053613:Janus Kinase 1; D053616:Janus Kinase 3